• In late February 2026, AdaptHealth Corp. reported full-year 2025 results showing slightly lower sales of US$3,244.86 million, a net loss of US$70.79 million driven in part by a US$127.99 million goodwill impairment, and new 2026 net revenue guidance of US$3.44 billion to US$3.51 billion, while continuing to pursue home medical equipment acquisitions funded partly by a US$100 million revolver draw.
• Alongside these results, management’s decision to raise revenue guidance, invest US$47.60 million in recently acquired home medical equipment assets, and keep its acquisition pipeline active offers fresh insight into how AdaptHealth is prioritizing growth and patient access despite reporting a loss.
• We’ll now examine how AdaptHealth’s higher 2026 revenue guidance and ongoing acquisition activity may reshape its investment narrative.

Find 49 companies with promising cash flow potential yet trading below their fair value.

AdaptHealth Investment Narrative Recap

To own AdaptHealth, you need to believe in the long term value of home medical equipment, recurring payer contracts, and the shift of care into the home, while accepting current profitability volatility. The latest results, including a full year net loss and another goodwill impairment, put more focus on the near term catalyst of execution under new contracts and acquisitions, and highlight balance sheet and reimbursement risk as the key near term concern.

The most relevant update here is AdaptHealth’s new 2026 net revenue guidance of US$3.44 billion to US$3.51 billion, issued alongside its 2025 results. That guidance, together with continued HME acquisitions supported by a US$100 million revolver draw, sits at the center of the immediate catalyst: whether the company can translate scale and contract wins into cleaner earnings, despite ongoing regulatory and integration risks.

Yet beneath the higher revenue guidance, investors should be aware that recurring goodwill impairments and increased leverage could start to...

AdaptHealth’s narrative projects $4.0 billion revenue and $157.7 million earnings by 2028.

Uncover how AdaptHealth's forecasts yield a $13.12 fair value, a 38% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts were already more cautious, assuming revenue of about US$3.8 billion and earnings of roughly US$168 million by 2028, and the latest loss plus new acquisitions may reinforce their concern that higher infrastructure costs and payer pressure could weigh on margins for longer, so it is worth comparing these more pessimistic expectations with your own view before deciding how this new guidance changes the story.

Explore 3 other fair value estimates on AdaptHealth - why the stock might be worth over 3x more than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your AdaptHealth research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free AdaptHealth research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate AdaptHealth's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Invest in the nuclear renaissance through our list of 85 elite nuclear energy infrastructure plays powering the global AI revolution.
• We've uncovered the 16 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Uncover the next big thing with 31 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.